|
Patient
|
Dose
|
Age
|
Sex
|
P/R
|
Curative
|
MTD
|
Tumor no.
|
Tumor
|
Background liver
|
CP
|
ALT
|
PLT
|
Prognosis
|
|---|
|
no.
| | | | |
treatment
| | |
histology
|
F
|
A
| | | |
2 yrs
|
4.5 yrs
|
|---|
|
1
|
300
|
70
|
F
|
P
|
RFA
|
15
|
2
|
m-p
|
4
|
2
|
A
|
112
|
7.9
|
Rec
|
Rec
|
|
2
|
600
|
72
|
F
|
R
|
RFA
|
20
|
2
|
w
|
4
|
2
|
A
|
40
|
7.9
|
Rec
|
Rec λ
|
|
3
|
300
|
58
|
M
|
P
|
resection
|
25
|
1
|
m-p
|
2
|
1
|
A
|
16
|
19.2
|
nonRec
|
nonRec
|
|
4
|
600
|
54
|
M
|
P
|
resection
|
25
|
1
|
m-p
|
3
|
2
|
A
|
57
|
16.4
|
nonRec
|
Rec
|
|
5
|
600
|
60
|
F
|
P
|
RFA
|
23
|
1
|
m-p
|
4
|
2
|
B
|
23
|
6.4
|
nonRec
|
nonRec
|
|
6
|
300
|
73
|
F
|
P
|
RFA
|
20
|
2
|
m-p
|
3
|
2
|
A
|
31
|
14.2
|
Rec
|
Rec λ
|
|
7
|
300
|
69
|
F
|
P
|
RFA
|
11
|
3
|
w-m
|
4
|
1
|
A
|
38
|
11.5
|
Rec
|
Rec λ
|
|
8
|
600
|
74
|
F
|
P
|
RFA
|
16
|
2
|
m-p
|
4
|
1
|
A
|
45
|
5.1
|
nonRec
|
Rec
|
|
9
|
600
|
65
|
M
|
R
|
RFA
|
10
|
1
|
m-p
|
2
|
1
|
A
|
29
|
16.5
|
nonRec
|
nonRec
|
|
10
|
600
|
59
|
M
|
P
|
resection
|
34
|
1
|
m-p
|
4
|
2
|
B
|
60
|
9.4
|
nonRec
|
nonRec
|
|
11
|
300
|
70
|
F
|
R
|
RFA
|
15
|
1
|
w-m
|
4
|
2
|
B
|
98
|
7
|
nonRec
|
nonRec
|
|
12
|
300
|
66
|
M
|
P
|
RFA
|
15
|
1
|
m-p
|
4
|
1
|
A
|
90
|
10.6
|
nonRec
|
nonRec
|
- Dose (mg/day), ALT(U/L), PLT(×104/μL), MTD (mm).
- F; female, M; male, P; primary HCC, R; (first) recurrent HCC, MTD; maximum tumor diameter, w; well-differentiated, m; moderately differentiated, p; poorly differentiated, F; fibrosis stage, A; activity grade, CP; Child-Pugh classification, ALT; alanine aminotransferase, PLT; platelet.
- Rec; recurrence, nonRec; non-recurrence, λ; death.
